Poor Glycemic Control Is Associated with Failure to Complete Neoadjuvant Therapy and Surgery in Patients with Localized Pancreatic Cancer

E. S Paul Rajamanickam, K. K. Christians, M. Aldakkak, A. N. Krepline, P. S. Ritch, B. George, B. A. Erickson, W. D. Foley, M. Aburajab, D. B. Evans, S. Tsai

Research output: Contribution to journalArticle

Abstract

Background: The impact of glycemic control in patients with pancreatic cancer treated with neoadjuvant therapy is unclear. Methods: Glycated hemoglobin (HbA1c) values were measured in patients with localized pancreatic cancer prior to any therapy (pretreatment) and after neoadjuvant therapy prior to surgery (preoperative). HbA1c levels greater than 6.5% were classified as abnormal. Patients were categorized based on the change in HbA1c levels from pretreatment to preoperative: GrpA, always normal; Gr B, worsened; GrpC, improved; and GrpD, always abnormal. Results: Pretreatment HbA1c levels were evaluable in 123 patients; there were 67 (55%) patients in GrpA, 8 (6%) in GrpB, 22 (18%) in GrpC, and 26 (21%) in GrpD. Of the 123 patients, 92 (75%) completed all intended therapy to include surgery; 57 (85%) patients in GrpA, 4 (50%) patients in GrpB, 16 (72%) patients in GrpC, and 15 (58%) patients in GrpD (p = 0.01). Elevated preoperative carbohydrate antigen 19-9 (CA19-9) (OR 0.22;[0.07–0.66]), borderline resectable (BLR) disease stage (OR 0.20;[0.01–0.45]) and abnormal preoperative HbA1c (OR 0.30;[0.11–0.90]) were negatively associated with completion of all intended therapy. Abnormal preoperative HbA1c was associated with a 2.74-fold increased odds of metastatic progression during neoadjuvant therapy (p = 0.08). Conclusions: Elevated preoperative HbA1c is associated with failure to complete neoadjuvant therapy and surgery and a trend for increased risk of metastatic progression.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalJournal of Gastrointestinal Surgery
DOIs
StateAccepted/In press - Nov 28 2016
Externally publishedYes

Fingerprint

Neoadjuvant Therapy
Pancreatic Neoplasms
Glycosylated Hemoglobin A
Therapeutics
Carbohydrates
Antigens

Keywords

  • Diabetes
  • Neoadjuvant therapy
  • Pancreatic cancer

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Cite this

Rajamanickam, E. S. P., Christians, K. K., Aldakkak, M., Krepline, A. N., Ritch, P. S., George, B., ... Tsai, S. (Accepted/In press). Poor Glycemic Control Is Associated with Failure to Complete Neoadjuvant Therapy and Surgery in Patients with Localized Pancreatic Cancer. Journal of Gastrointestinal Surgery, 1-10. https://doi.org/10.1007/s11605-016-3319-4

Poor Glycemic Control Is Associated with Failure to Complete Neoadjuvant Therapy and Surgery in Patients with Localized Pancreatic Cancer. / Rajamanickam, E. S Paul; Christians, K. K.; Aldakkak, M.; Krepline, A. N.; Ritch, P. S.; George, B.; Erickson, B. A.; Foley, W. D.; Aburajab, M.; Evans, D. B.; Tsai, S.

In: Journal of Gastrointestinal Surgery, 28.11.2016, p. 1-10.

Research output: Contribution to journalArticle

Rajamanickam, ESP, Christians, KK, Aldakkak, M, Krepline, AN, Ritch, PS, George, B, Erickson, BA, Foley, WD, Aburajab, M, Evans, DB & Tsai, S 2016, 'Poor Glycemic Control Is Associated with Failure to Complete Neoadjuvant Therapy and Surgery in Patients with Localized Pancreatic Cancer', Journal of Gastrointestinal Surgery, pp. 1-10. https://doi.org/10.1007/s11605-016-3319-4
Rajamanickam, E. S Paul ; Christians, K. K. ; Aldakkak, M. ; Krepline, A. N. ; Ritch, P. S. ; George, B. ; Erickson, B. A. ; Foley, W. D. ; Aburajab, M. ; Evans, D. B. ; Tsai, S. / Poor Glycemic Control Is Associated with Failure to Complete Neoadjuvant Therapy and Surgery in Patients with Localized Pancreatic Cancer. In: Journal of Gastrointestinal Surgery. 2016 ; pp. 1-10.
@article{dc66145cbe7949a59b1eb791427328c0,
title = "Poor Glycemic Control Is Associated with Failure to Complete Neoadjuvant Therapy and Surgery in Patients with Localized Pancreatic Cancer",
abstract = "Background: The impact of glycemic control in patients with pancreatic cancer treated with neoadjuvant therapy is unclear. Methods: Glycated hemoglobin (HbA1c) values were measured in patients with localized pancreatic cancer prior to any therapy (pretreatment) and after neoadjuvant therapy prior to surgery (preoperative). HbA1c levels greater than 6.5{\%} were classified as abnormal. Patients were categorized based on the change in HbA1c levels from pretreatment to preoperative: GrpA, always normal; Gr B, worsened; GrpC, improved; and GrpD, always abnormal. Results: Pretreatment HbA1c levels were evaluable in 123 patients; there were 67 (55{\%}) patients in GrpA, 8 (6{\%}) in GrpB, 22 (18{\%}) in GrpC, and 26 (21{\%}) in GrpD. Of the 123 patients, 92 (75{\%}) completed all intended therapy to include surgery; 57 (85{\%}) patients in GrpA, 4 (50{\%}) patients in GrpB, 16 (72{\%}) patients in GrpC, and 15 (58{\%}) patients in GrpD (p = 0.01). Elevated preoperative carbohydrate antigen 19-9 (CA19-9) (OR 0.22;[0.07–0.66]), borderline resectable (BLR) disease stage (OR 0.20;[0.01–0.45]) and abnormal preoperative HbA1c (OR 0.30;[0.11–0.90]) were negatively associated with completion of all intended therapy. Abnormal preoperative HbA1c was associated with a 2.74-fold increased odds of metastatic progression during neoadjuvant therapy (p = 0.08). Conclusions: Elevated preoperative HbA1c is associated with failure to complete neoadjuvant therapy and surgery and a trend for increased risk of metastatic progression.",
keywords = "Diabetes, Neoadjuvant therapy, Pancreatic cancer",
author = "Rajamanickam, {E. S Paul} and Christians, {K. K.} and M. Aldakkak and Krepline, {A. N.} and Ritch, {P. S.} and B. George and Erickson, {B. A.} and Foley, {W. D.} and M. Aburajab and Evans, {D. B.} and S. Tsai",
year = "2016",
month = "11",
day = "28",
doi = "10.1007/s11605-016-3319-4",
language = "English (US)",
pages = "1--10",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",

}

TY - JOUR

T1 - Poor Glycemic Control Is Associated with Failure to Complete Neoadjuvant Therapy and Surgery in Patients with Localized Pancreatic Cancer

AU - Rajamanickam, E. S Paul

AU - Christians, K. K.

AU - Aldakkak, M.

AU - Krepline, A. N.

AU - Ritch, P. S.

AU - George, B.

AU - Erickson, B. A.

AU - Foley, W. D.

AU - Aburajab, M.

AU - Evans, D. B.

AU - Tsai, S.

PY - 2016/11/28

Y1 - 2016/11/28

N2 - Background: The impact of glycemic control in patients with pancreatic cancer treated with neoadjuvant therapy is unclear. Methods: Glycated hemoglobin (HbA1c) values were measured in patients with localized pancreatic cancer prior to any therapy (pretreatment) and after neoadjuvant therapy prior to surgery (preoperative). HbA1c levels greater than 6.5% were classified as abnormal. Patients were categorized based on the change in HbA1c levels from pretreatment to preoperative: GrpA, always normal; Gr B, worsened; GrpC, improved; and GrpD, always abnormal. Results: Pretreatment HbA1c levels were evaluable in 123 patients; there were 67 (55%) patients in GrpA, 8 (6%) in GrpB, 22 (18%) in GrpC, and 26 (21%) in GrpD. Of the 123 patients, 92 (75%) completed all intended therapy to include surgery; 57 (85%) patients in GrpA, 4 (50%) patients in GrpB, 16 (72%) patients in GrpC, and 15 (58%) patients in GrpD (p = 0.01). Elevated preoperative carbohydrate antigen 19-9 (CA19-9) (OR 0.22;[0.07–0.66]), borderline resectable (BLR) disease stage (OR 0.20;[0.01–0.45]) and abnormal preoperative HbA1c (OR 0.30;[0.11–0.90]) were negatively associated with completion of all intended therapy. Abnormal preoperative HbA1c was associated with a 2.74-fold increased odds of metastatic progression during neoadjuvant therapy (p = 0.08). Conclusions: Elevated preoperative HbA1c is associated with failure to complete neoadjuvant therapy and surgery and a trend for increased risk of metastatic progression.

AB - Background: The impact of glycemic control in patients with pancreatic cancer treated with neoadjuvant therapy is unclear. Methods: Glycated hemoglobin (HbA1c) values were measured in patients with localized pancreatic cancer prior to any therapy (pretreatment) and after neoadjuvant therapy prior to surgery (preoperative). HbA1c levels greater than 6.5% were classified as abnormal. Patients were categorized based on the change in HbA1c levels from pretreatment to preoperative: GrpA, always normal; Gr B, worsened; GrpC, improved; and GrpD, always abnormal. Results: Pretreatment HbA1c levels were evaluable in 123 patients; there were 67 (55%) patients in GrpA, 8 (6%) in GrpB, 22 (18%) in GrpC, and 26 (21%) in GrpD. Of the 123 patients, 92 (75%) completed all intended therapy to include surgery; 57 (85%) patients in GrpA, 4 (50%) patients in GrpB, 16 (72%) patients in GrpC, and 15 (58%) patients in GrpD (p = 0.01). Elevated preoperative carbohydrate antigen 19-9 (CA19-9) (OR 0.22;[0.07–0.66]), borderline resectable (BLR) disease stage (OR 0.20;[0.01–0.45]) and abnormal preoperative HbA1c (OR 0.30;[0.11–0.90]) were negatively associated with completion of all intended therapy. Abnormal preoperative HbA1c was associated with a 2.74-fold increased odds of metastatic progression during neoadjuvant therapy (p = 0.08). Conclusions: Elevated preoperative HbA1c is associated with failure to complete neoadjuvant therapy and surgery and a trend for increased risk of metastatic progression.

KW - Diabetes

KW - Neoadjuvant therapy

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84997795492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997795492&partnerID=8YFLogxK

U2 - 10.1007/s11605-016-3319-4

DO - 10.1007/s11605-016-3319-4

M3 - Article

C2 - 27896658

AN - SCOPUS:84997795492

SP - 1

EP - 10

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

ER -